IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd (IOLCP) last reported results for the quarter ended Jun 2026, with sales of ₹756 crore and net profit of ₹64 crore. The stock last traded at ₹209, a market capitalisation of ₹6,133 crore, on a P/E of 34.7. Over the past 52 weeks the stock has ranged between ₹67.1 and ₹219. Figures are as of 6 Oct 2026 and are not real time.
IOL Chemicals & Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹209
- Market cap
- ₹6,133 cr
- Stock P/E
- 34.7
- Book value
- ₹61.3
- ROE
- 8.41%
- ROCE
- 11.3%
- Dividend yield
- 0.49%
- 52w high / low
- 219/67.1
Metrics as of 6 Oct 2026. Not real time.
Track IOL Chemicals & Pharmaceuticals Ltd
Cruxal reads every IOL Chemicals & Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
IOL Chemicals & Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 2%
- TTM
- 19%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 2%
- TTM
- 68%
- 10 Years
- 23%
- 5 Years
- 11%
- 3 Years
- 30%
- 1 Year
- 98%
- 10 Years
- %
- 5 Years
- 9%
- 3 Years
- 8%
- Last Year
- 8%
IOL Chemicals & Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹756 cr, up 37.0% from ₹552 cr a year earlier. Net profit was ₹64 cr, up 88.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 |
| Expenses | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 |
| Operating profit | 42 | 47 | 63 | 62 | 57 | 57 | 92 | 103 |
| OPM % | 8% | 9% | 12% | 11% | 10% | 10% | 15% | 14% |
| Other income | 6 | 4 | 5 | 7 | 7 | -6 | 2 | 8 |
| Interest | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 |
| Depreciation | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 |
| Profit before tax | 26 | 28 | 45 | 46 | 40 | 28 | 71 | 87 |
| Tax % | 26% | 26% | 30% | 25% | 26% | 25% | 25% | 26% |
| Net profit | 19 | 21 | 31 | 34 | 30 | 21 | 53 | 64 |
| EPS (₹) | 0.65 | 0.70 | 1.07 | 1.16 | 1.02 | 0.70 | 1.81 | 2.19 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
IOL Chemicals & Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 | 2,524 |
| Operating profit | 259 | 226 | 231 | 202 | 270 | 310 |
| OPM % | 12% | 10% | 11% | 10% | 12% | 12% |
| Net profit | 168 | 139 | 134 | 101 | 138 | 168 |
| EPS (₹) | 5.71 | 4.74 | 4.58 | 3.44 | 4.69 | 5.72 |
TTM is the trailing twelve months to the most recent quarter.
IOL Chemicals & Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 59 | 59 | 59 | 59 | 59 |
| Reserves | 1,334 | 1,449 | 1,553 | 1,629 | 1,740 |
| Borrowings | 44 | 80 | 33 | 117 | 135 |
| Other liabilities | 526 | 435 | 600 | 577 | 653 |
| Total liabilities | 1,962 | 2,022 | 2,244 | 2,382 | 2,587 |
| Fixed assets | 561 | 752 | 933 | 1,171 | 1,182 |
| CWIP | 105 | 90 | 101 | 22 | 96 |
| Investments | 2 | 20 | 20 | 21 | 21 |
| Other assets | 1,294 | 1,161 | 1,190 | 1,169 | 1,289 |
| Total assets | 1,962 | 2,022 | 2,244 | 2,382 | 2,587 |
As reported by the company. Total assets equal total liabilities by construction.
IOL Chemicals & Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 93 | 122 | 290 | 179 | 214 |
| Cash from investing | -121 | -120 | -191 | -154 | -198 |
| Cash from financing | -2 | -4 | -92 | 46 | -29 |
| Net cash flow | -29 | -2 | 6 | 70 | -13 |
| Free cash flow | -58 | -87 | 17 | -34 | 43 |
| CFO / operating profit | 60% | 75% | 144% | 97% | 93% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
IOL Chemicals & Pharmaceuticals Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | 14% | 12% | 9% | 11% |
| Debtor days | 79 | 83 | 81 | 90 | 95 |
| Inventory days | 95 | 77 | 111 | 95 | 91 |
| Days payable | 95 | 74 | 123 | 112 | 118 |
| Cash conversion cycle | 79 | 86 | 69 | 73 | 68 |
| Working capital days | 71 | 72 | 71 | 58 | 53 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
IOL Chemicals & Pharmaceuticals Ltd shareholding pattern
Promoters held 62.28% at Jun 2026, up from 52.62% at Jun 2025. FIIs 4.87% and DIIs 0.43%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 48.19% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 57.48% | 62.28% |
| FIIs | 1.63% | 1.49% | 1.47% | 2.59% | 2.25% | 2.08% | 1.72% | 4.87% |
| DIIs | 0.07% | 0.08% | 0.07% | 0.02% | 0.05% | 0.03% | 0.02% | 0.43% |
| Public | 50.11% | 45.81% | 45.84% | 44.76% | 45.10% | 45.26% | 40.78% | 32.41% |
| No. of shareholders | 1,25,979 | 1,26,701 | 1,30,002 | 1,25,040 | 1,36,129 | 1,33,531 | 1,31,550 | 1,19,311 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd corporate filings
- Certificate under Regulation 75(5) of SEBI (DP) RegulationsCompany Updatelow impact
- IOL Chemicals & Pharmaceuticals receives CEP for Fenofibrate Process IICompany Updatemedium impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has been granted a Certificate of Suitability (CEP) for…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- IOL Chemicals & Pharmaceuticals secures EU-REACH registration for TriacetinCompany Updatemedium impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has successfully completed the EU-REACH registration for…
Read the full analysis - IOL Chemicals & Pharmaceuticals Ltd schedules analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has announced a scheduled meeting with analysts and…
Read the full analysis - IOL Chemicals & Pharmaceuticals Ltd schedules analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has announced a scheduled meeting with analysts and…
Read the full analysis - IOL Chemicals & Pharmaceuticals Ltd issues reminder to shareholders for KYC updatesCompany Updatelow impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals Ltd has issued a formal reminder to its shareholders to…
Read the full analysis - IOL Chemicals & Pharmaceuticals releases transcript of investor and analyst business update callCompany Updatelow impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has filed the transcript of its business update call held…
Read the full analysis - IOL Chemicals & Pharmaceuticals Ltd releases audio recording of investor and analyst business update callCompany Updatelow impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has made the audio recording of its recent business…
Read the full analysis - IOL Chemicals & Pharmaceuticals schedules analyst and investor conference callCompany Updatelow impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has announced an analyst and investor meet to discuss…
Read the full analysis - IOL Chemicals & Pharmaceuticals announces capacity expansion for Ibuprofen, new CDMO business, and specialty chemicals facilityCompany Updatemedium impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has announced a strategic expansion plan involving…
Read the full analysis - IOL Chemicals and Pharmaceuticals Limited concludes 39th Annual General Meeting with all resolutions passedAGM/EGMlow impact
Cruxal's analysis: IOL Chemicals and Pharmaceuticals Limited has successfully concluded its 39th Annual…
Read the full analysis - IOL Chemicals and Pharmaceuticals Limited Concludes 39th Annual General Meeting with All Resolutions PassedAGM/EGMlow impact
Cruxal's analysis: IOL Chemicals and Pharmaceuticals Limited has successfully concluded its 39th Annual…
Read the full analysis - IOL Chemicals & Pharmaceuticals schedules analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals has announced a scheduled meeting with analysts and…
Read the full analysis - IOL Chemicals and Pharmaceuticals Reports Strong Q1 FY27 Performance with 37% Revenue Growth and 90% PAT SurgeCompany Updatehigh impact
Cruxal's analysis: IOL Chemicals and Pharmaceuticals Limited delivered a robust Q1 FY27, reporting revenue…
Read the full analysis - IOL Chemicals & Pharmaceuticals Ltd submits newspaper publication of financial resultsCompany Updatelow impact
Cruxal's analysis: IOL Chemicals & Pharmaceuticals Ltd has submitted the mandatory newspaper publication…
Read the full analysis - IOL Chemicals and Pharmaceuticals Limited releases audio recording of Q1 FY2027 earnings callCompany Updatelow impact
Cruxal's analysis: IOL Chemicals and Pharmaceuticals Limited has filed the audio recording of its analyst…
Read the full analysis - IOL Chemicals and Pharmaceuticals reports strong Q1 FY27 performance with 37.1% YoY revenue growth and 89.9% YoY PAT growthCompany Updatehigh impact
Cruxal's analysis: IOL Chemicals and Pharmaceuticals Limited delivered robust Q1 FY27 results, with revenue…
Read the full analysis - IOL Chemicals and Pharmaceuticals Limited schedules 39th Annual General Meeting for September 2, 2026Company Updatelow impact
Cruxal's analysis: IOL Chemicals and Pharmaceuticals Limited has announced that its 39th Annual General…
Read the full analysis - IOL Chemicals and Pharmaceuticals reports strong Q1 FY27 performance with 89.7% YoY net profit growthCompany Updatehigh impact
Cruxal's analysis: IOL Chemicals and Pharmaceuticals Limited reported robust financial results for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.